New anti-coagulant therapies set to revitalise clinical haemotology practice.
J
J
Aalbers
P
P
Wagenaar
E
E
Klug
D017130:Angioplasty; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy*; D016893:Carotid Stenosis / Q000628:therapy; D016894:Endarterectomy, Carotid; D019317:Evidence-Based Medicine; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006405:Hematology; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy; D015912:Thrombolytic Therapy
D000925:Anticoagulants; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D010975:Platelet Aggregation Inhibitors; C036309:fibrin fragment D